Cloud Security Authors: Zakia Bouachraoui, Pat Romanski, Elizabeth White, Yeshim Deniz, Liz McMillan

News Feed Item

Stock Sector Focuses On Record Sales of NovaBay's Avenova(R) in Interview With Sales and Marketing VP

In an interview With ​Stock-Sector ​at the American Academy of Ophthalmology Meeting in Las Vegas, NovaBay's Glenn Moro Explains Why Sales of ​Avenova ​Eyelid and Eyelash Cleanser Reached a Record $1.1 Million in the Third Quarter -- and Continue to Climb

NEW YORK, NY--(Marketwired - November 16, 2015) - STOCK-SECTOR.COM, ​an online source of news about promising medical, technology and energy companies, today released an interview with Glenn Moro, Vice President of Avenova®Sales and Marketing at ​NovaBay Pharmaceuticals ​(NYSE: NBY), an Emeryville, CA, a biopharmaceutical company commercializing and developing topical non­antibiotic antimicrobial products for the global eye care market.

Stock ­Sector caught up with Moro at the ​American Academy of Ophthalmology meeting​in Los Vegas, Nov. 14­-17, where NovaBay is discussing the benefits-and the rapidly rising sales-of its innovative eyelid and eyelash cleanser, ​Avenova®.

As Moro said in the interview ​[VIDEO] ​"We just had our biggest quarter ever, with $1.1 million in sales." Those third quarter numbers represented a 40% jump over second quarter sales. Moreover, fourth quarter sales are expected to rise at an even faster rate: Sales in the first month were 50% higher than those in the first month of the third quarter. "We are showing a nice trend -- and we are very excited," said Moro.

In the interview Moro explained that revenues come from both selling ​Avenovadirectly to doctors (who then bill their patients) and selling the eyelid cleanser through pharmacies after doctors write prescriptions. The prescription side of the business is growing the fastest. In January 2015, doctors were writing just a couple hundred prescriptions per month. "Now we're up to 6500 a month," Moro said. "We really excited about the prescription business. We believe it will be the majority of the business in the future."

Avenovasales are climbing for two reasons, Moro said. One is that the product is unique. Avenovais the only eyelid cleanser to contain Neutrox, NovaBay's proprietary pure hypochlorous acid (HOCl). While other products may include HOCl among their ingredients, they also contain substances like bleach, which is both less effective against microbes than Neutrox in lab tests and is toxic to cells. In vitro testing shows that Neutrox not only kills many strains of bacteria in seconds, it also neutralizes the toxins that the microbes produce, while being completely safe.

The second reason is that both ​patients​ and ​doctors​ have found that a regimen of daily lid hygiene using ​Avenovahas been remarkably successful in managing often ­painful eye conditions like blepharitis and meibomian gland dysfunction (or dry eye). Those conditions are caused by bacteria on the eyelids and affect an estimated 30 million Americans. Once doctors actually try Avenova, any skepticism they might have had about the product vanishes, said Moro. Many of their patients say that the product has brought the first relief they've had in years. ​Avenova, Moro said, "has had a profound impact on patients' lives."

That's why NovaBay is working so hard to get the word out to more doctors about the benefits of Avenova-and why Moro expects that 2016 will bring "a significant increase in sales."

Stock­-Sector is an online source of news about promising medical, technology, and energy companies. ​Stock­-Sector was created out of necessity, to provide a glimpse of the financial markets in sectors relevant to the investor. We strive to deliver easily digestible content to the overburdened stockholder. Another significant focus of ours is to establish compelling media to heighten the experience in neglected humdrum industries.

The statements contained herein may include statements of future expectations and other forward­looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward­looking by reason of context, the words "may", "will", "should," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" and similar expressions identify forward­looking statements.

Actual results, performance or events may differ materially from those in such statements due to, without limitation, (i) general economic conditions, (ii) performance of financial markets, including emerging markets, and including market volatility, liquidity and credit events (iii) the frequency and severity of insured loss events, including from natural catastrophes and including the development of loss expenses, (iv) mortality and morbidity levels and trends, (v) persistency levels, (vi) the extent of credit defaults, (vii) interest rate levels, (viii) currency exchange rates including the Euro/U.S. Dollar exchange rate, (ix) changing levels of competition, (x) changes in laws and regulations, (xi) changes in the policies of central banks and/or foreign governments, (xii) the impact of acquisitions, including related integration issues, (xiii) reorganization measures, and (xiv) general competitive factors, in each case on a local, regional, national and/or global basis.

Embedded Video Available: https://youtu.be/7Dtyx7H9-lY

Contact Stock-Sector [email protected] for more information.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

IoT & Smart Cities Stories
Nicolas Fierro is CEO of MIMIR Blockchain Solutions. He is a programmer, technologist, and operations dev who has worked with Ethereum and blockchain since 2014. His knowledge in blockchain dates to when he performed dev ops services to the Ethereum Foundation as one the privileged few developers to work with the original core team in Switzerland.
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
Whenever a new technology hits the high points of hype, everyone starts talking about it like it will solve all their business problems. Blockchain is one of those technologies. According to Gartner's latest report on the hype cycle of emerging technologies, blockchain has just passed the peak of their hype cycle curve. If you read the news articles about it, one would think it has taken over the technology world. No disruptive technology is without its challenges and potential impediments t...
If a machine can invent, does this mean the end of the patent system as we know it? The patent system, both in the US and Europe, allows companies to protect their inventions and helps foster innovation. However, Artificial Intelligence (AI) could be set to disrupt the patent system as we know it. This talk will examine how AI may change the patent landscape in the years to come. Furthermore, ways in which companies can best protect their AI related inventions will be examined from both a US and...
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
Bill Schmarzo, Tech Chair of "Big Data | Analytics" of upcoming CloudEXPO | DXWorldEXPO New York (November 12-13, 2018, New York City) today announced the outline and schedule of the track. "The track has been designed in experience/degree order," said Schmarzo. "So, that folks who attend the entire track can leave the conference with some of the skills necessary to get their work done when they get back to their offices. It actually ties back to some work that I'm doing at the University of San...
When talking IoT we often focus on the devices, the sensors, the hardware itself. The new smart appliances, the new smart or self-driving cars (which are amalgamations of many ‘things'). When we are looking at the world of IoT, we should take a step back, look at the big picture. What value are these devices providing. IoT is not about the devices, its about the data consumed and generated. The devices are tools, mechanisms, conduits. This paper discusses the considerations when dealing with the...
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
Dynatrace is an application performance management software company with products for the information technology departments and digital business owners of medium and large businesses. Building the Future of Monitoring with Artificial Intelligence. Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more busine...